文献速递病毒性肝炎新发突发、热带与寄生虫病

免疫检查点抑制剂诱导的HBV标志物快速下降改善HBV相关HCC预后

Immune Checkpoint Inhibitor-Induced Rapid Decline in Hepatitis B Virus Markers Improves the Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma Patients.
PubMed 文献 · J Infect Dis · 2026-01-01

该回顾性队列纳入318例HBV相关HCC患者(ICI组268例,非ICI组50例),中位随访8.1个月。病毒学应答与更好的生存和肿瘤应答相关(HR 1.64-8.06)。

要点

  • ICI治疗可显著降低HBV相关HCC患者的HBsAg、HBV DNA、HBV RNA和HBcrAg水平。
  • PD-1抑制剂病毒学应答优于PD-L1抑制剂(HR 2.04-5.43)。
  • 实现病毒学应答与更好生存和肿瘤应答相关(HR 1.64-8.06)。

核心结论

  • ICI在HBV相关HCC中显示双重治疗效应:显著降低多种HBV标志物,并与抗病毒治疗协同改善预后。

研究设计与样本

  • 回顾性队列研究,纳入318例HBV相关HCC患者,其中ICI组268例(联合或不联合靶向治疗),非ICI组50例(仅靶向治疗)。

主要发现

  • 中位随访8.1个月,ICI组所有HBV标志物下降幅度显著大于非ICI组。
  • PD-1抑制剂病毒学应答显著优于PD-L1抑制剂(HR 2.04-5.43)。
  • 基线HBV标志物水平较低者总生存显著更好;实现病毒学应答者生存和肿瘤应答显著更好(HR 1.64-8.06)。

临床怎么用

  • 对HBV相关HCC患者接受ICI治疗时,应监测qHBsAg、HBV DNA、HBV RNA和HBcrAg等标志物。
  • 实现病毒学应答与更好预后相关,支持持续病毒学抑制对优化HCC结局的重要性。

局限性

  • 回顾性研究设计。
  • 非ICI组样本量较小(50例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Limited research exists on immune checkpoint inhibitors (ICIs)' antiviral efficacy in hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). This study aimed to evaluate the impact of ICIs on multiple HBV markers and its correlation with HCC prognosis. METHODS: A retrospective cohort study was performed on 318 HBV-related HCC patients, including 268 who received ICIs (with/without targeted therapy; ICI group) and 50 who received targeted therapy alone (non-ICI group). Levels of quantitative HBsAg (qHBsAg), HBV DNA, HBV RNA, and HBcrAg were monitored. Tumor response was evaluated using RECIST 1.1. RESULTS: Over a median 8.1-month follow-up, the ICI group showed a significantly greater decrease in all HBV markers. At week 96, the ICI group showed significantly higher cumulative incidences of HBsAg response (loss or ≥0.5 Log10 decline) (41.6% vs 14.9%, P = .006) and HBcrAg response (negativity or ≥1 Log10 decline) (46.3% vs 18.1%, P = .007) than non-ICI group and a significantly faster achievement rate of HBV RNA response (negativity or ≥0.5 Log10 decline) (hazard ratio [HR]: 1.80, 95% CI: 1.08-2.99, P = .021). Notably, the PD-1 inhibitors showed significantly better virological response efficacy than PD-L1 inhibitors (HR = 2.04-5.43). The patients with lower levels of HBV markers at enrollment demonstrated significantly better overall survival. Moreover, patients achieving virological response were associated with significantly better survival outcomes and tumor response, with HR ranging 1.64-8.06. CONCLUSIONS: Immune checkpoint inhibitors demonstrate dual therapeutic effects in HBV-related HCC, significantly reducing multiple HBV markers while concurrently enhancing prognosis in combination with antiviral therapy, emphasizing the importance of sustained virological suppression for optimal HCC outcomes.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Ran Y, Zhu M, Wang K, et al. Immune Checkpoint Inhibitor-Induced Rapid Decline in Hepatitis B Virus Markers Improves the Prognosis of Hepatitis B Virus-Related Hepatocellular Carcinoma Patients. J Infect Dis. 2026. PMID: 41540638. doi:10.1093/infdis/jiag036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。